NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 122 filers reported holding NURIX THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,140,117 | -19.0% | 145,053 | +3.0% | 0.00% | – |
| Q2 2023 | $1,407,491 | +124.7% | 140,890 | +99.8% | 0.00% | – |
| Q1 2023 | $626,298 | -21.9% | 70,529 | -3.4% | 0.00% | – |
| Q4 2022 | $801,584 | -17.4% | 73,004 | -2.0% | 0.00% | – |
| Q3 2022 | $971,000 | +44.3% | 74,529 | +40.3% | 0.00% | – |
| Q2 2022 | $673,000 | -94.3% | 53,104 | -93.7% | 0.00% | -100.0% |
| Q1 2022 | $11,802,000 | -64.9% | 842,373 | -27.5% | 0.00% | -60.0% |
| Q4 2021 | $33,649,000 | -8.4% | 1,162,316 | -5.2% | 0.01% | -16.7% |
| Q3 2021 | $36,732,000 | -0.7% | 1,226,058 | -12.1% | 0.01% | 0.0% |
| Q2 2021 | $37,007,000 | -12.5% | 1,394,891 | +2.5% | 0.01% | -14.3% |
| Q1 2021 | $42,296,000 | -47.4% | 1,360,426 | -44.4% | 0.01% | -53.3% |
| Q4 2020 | $80,342,000 | -31.2% | 2,447,584 | -27.3% | 0.02% | -37.5% |
| Q3 2020 | $116,762,000 | – | 3,368,522 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |